GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: Cubicin® | LY-146032 | LY146032
daptomycin is an approved drug (FDA (2003), EMA (2006))
Compound class:
Natural product
Comment: Daptomycin is a cyclic lipopeptide antibacterial with broad-spectrum activity against Gram-positive bacteria [2]. It is a bacterial metabolite that was isolated from Streptomyces roseosporus [1]. Daptomycin rapidly depolarizes the bacterial cell membrane which disrupts DNA, RNA and protein synthesis and results in cell death.
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Daptomycin is used to treat complicated bacterial infections of the skin and soft tissues, Staphylococcus aureus bacteraemia, and MRSA. It was removed from the World Health Organization's List of Essential Medicines in 2019, as it did not meet the revised criteria for inclusion on the Model Lists as a Reserve group agent [4]. |
External links ![]() |
|
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com |